返回
Regeneron Pharmaceuticals Inc（REGN）價格
REGN 股價走勢圖
REGN 收益
Regeneron Pharmaceuticals Inc
$733.04
-1.19%
$-8.87
收盤價：Jan 16, 16:00:00 GMT-5
$736
0.4%
$2.96
盤後：Jan 16, 20:00:00 GMT-5
關鍵數據
前收市價
$741.92
開盤價
$749.09
當日範圍
$726.43 - $749.09
52週區間
$476.49 - $821.11
交易量
1.6M
平均成交量
991.1K
每股盈餘 (TTM)
41.78
股息收益率
--
市值
$77.3B
什麼是 REGN？
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.